We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technology Can Diagnose Infections in Minutes

By LabMedica International staff writers
Posted on 08 Jul 2021
The detection and identification of bacteria currently rely on enrichment steps such as bacterial culture and nucleic acid amplification to increase the concentration of target analytes. More...
These steps increase assay time, cost and complexity, making it difficult to realize a truly rapid point-of-care test.

Existing practice typically requires sending samples to laboratories to be cultured, a process that can take days. Providing immediate results to patients can reduce the spread of infection, improve patients' quality of life and simplify the work of busy clinicians. A new technology can distinguish strains of the same bacteria that can be treated with antibiotics from others that are resistant to antibiotics, a critical distinction that can help battle the growing problem of antimicrobial resistance, or AMR.

Biomedical Scientists at the McMaster University (Hamilton, ON, Canada) and their associates developed an electrical assay that uses electroactive RNA-cleaving DNAzymes (e-RCDs) to identify specific bacterial targets and subsequently release a DNA barcode for transducing a signal onto an electrical chip. Integrating e-RCDs into a two-channel electrical chip with nanostructured electrodes provides the analytical sensitivity and specificity needed for clinical analysis.

The microchip analyzes a droplet of bodily fluid such as blood, urine or saliva, using molecules that can detect the specific protein signature of an infection. The device, about the size of a USB stick, plugs into a smartphone, which displays the result. The e-RCD assay is capable of detecting 10 CFU (equivalent to 1,000 CFU mL-1) of Escherichia coli selectively from a panel containing multiple non-specific bacterial species. Clinical evaluation of this assay using 41 patient urine samples demonstrated a diagnostic sensitivity of 100% and specificity of 78% at an analysis time of less than one hour compared with the several hours needed for currently used culture-based methods.

Yingfu Li, PhD, a Professor of Biochemistry and a senior author of the study, said, “This technology is very versatile and we're getting very close to using the same technology for COVID-19 testing. As scientists, we want to enable things. We are knowledgeable in different scientific and engineering principles, and when you put them together to help people, that is a special feeling. Having the chance to impact society is the reason we all do this work.” The study was published on June 24, 2021 in the journal Nature Chemistry.

Related Links:
McMaster University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.